All News

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy

May 2020

Rigvir Holding concludes a deal with Chinese biotech company Sinorda Biomedicine

May 2020

Rigvir holding successfully attracted investments of EUR 500,000

The investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

April 2020

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

April 2020

Attention, counterfeit!

March 2020

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

February 2020

A Case Report published: Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir

November 2019

Rigvir improves control and circulation of medicines

May 2019

Rigvir follow-up titre analyses completed

March 2019

Rigvir Group made a strategic decision temporarily suspend the distribution of Rigvir in Latvia

March 2019

Rigvir Group has sold International Virotherapy Center

December 2018

ESMO 2018 (Munich): The World’s Premier Congress in Medical Oncology

October 2018

Rigvir Group Assigns the Clinic to a New Partner

October 2018

The Regional Administrative Court Concludes: The Manufacturer of Rigvir has not Committed Unfair Commercial Practices

October 2018

The discussion on the pharmaceutical industry at The Public Health Subcommittee of the parliament of Republic of Latvia

October 2018

Presentation of scholarships by Vītols Fund and Rigvir Group

September 2018

IVC organizes international Melanoma Awareness Days

July 2018

Virotherapy combined treatment – new paradigm in cancer treatment

May 2018

Rigvir Group becomes a biotech company

May 2018

Oncolytic virotherapy approved in Uzbekistan

April 2018

Rigvir Group company has recieved a €994,000 loan from EBRD and US private capital owned bank

December 2017

Vītols Foundation and Rigvir holding scholarships

September 2017

Rigvir Group receives “Seal of Exellence”

July 2017

WIPO Intellectual Property Award for Rigvir Group

April 2017

Discussion about oncolytic virotherapy in Latvian Academy of sciences

January 2017

Rigvir holding takes part in Central and Eastern Europe countries and China summit

November 2016

Participation in 24th World Cancer Congress 2016

November 2016

SME Instrument Innovators’ Summit 2016

October 2016

Melanoma screening campaign calls for preventive skin check-ups

September 2016

Horizon 2020 grant for cancer virotherapy medicine

July 2016

Oncolytic virotherapy approved in Armenia

May 2016

Opening of the Global Virotherapy Cancer Clinic

February 2016

Aina Muceniece Virotherapy Foundation established

February 2016

Rigvir holding announces a grant programme

January 2016

Agreement between Rigvir holding and charity foundation “Vītolu fonds”

January 2016

IV Virotherapy conference

November 2015

New clinical guidelines recommends oncolytic virotherapy

August 2015

Oncolytic virotherapy approved in Georgia

May 2015

Oncolytic virotherapy with RIGVIR^® is reimbursable medication

2011

Opening of the International Viroterapy Center (IVC)

2008

State Agency of Medicines of the Republic of Latvia registers RIGVIR^®

2004

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy

Rigvir Holding concludes a deal with Chinese biotech company Sinorda Biomedicine

Rigvir holding successfully attracted investments of EUR 500,000

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

Attention, counterfeit!

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

A Case Report published: Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir

Rigvir improves control and circulation of medicines

Rigvir follow-up titre analyses completed

Rigvir Group made a strategic decision temporarily suspend the distribution of Rigvir in Latvia

Rigvir Group has sold International Virotherapy Center

ESMO 2018 (Munich): The World’s Premier Congress in Medical Oncology

Rigvir Group Assigns the Clinic to a New Partner

The Regional Administrative Court Concludes: The Manufacturer of Rigvir has not Committed Unfair Commercial Practices

The discussion on the pharmaceutical industry at The Public Health Subcommittee of the parliament of Republic of Latvia

Presentation of scholarships by Vītols Fund and Rigvir Group

IVC organizes international Melanoma Awareness Days

Virotherapy combined treatment – new paradigm in cancer treatment

Rigvir Group becomes a biotech company

Oncolytic virotherapy approved in Uzbekistan

Rigvir Group company has recieved a €994,000 loan from EBRD and US private capital owned bank

Vītols Foundation and Rigvir holding scholarships

Rigvir Group receives “Seal of Exellence”

WIPO Intellectual Property Award for Rigvir Group

Discussion about oncolytic virotherapy in Latvian Academy of sciences

Rigvir holding takes part in Central and Eastern Europe countries and China summit

Participation in 24th World Cancer Congress 2016

SME Instrument Innovators’ Summit 2016

Melanoma screening campaign calls for preventive skin check-ups

Horizon 2020 grant for cancer virotherapy medicine

Oncolytic virotherapy approved in Armenia

Opening of the Global Virotherapy Cancer Clinic

Aina Muceniece Virotherapy Foundation established

Rigvir holding announces a grant programme

Agreement between Rigvir holding and charity foundation “Vītolu fonds”

IV Virotherapy conference

New clinical guidelines recommends oncolytic virotherapy

Oncolytic virotherapy approved in Georgia

Oncolytic virotherapy with RIGVIR® is reimbursable medication

Opening of the International Viroterapy Center (IVC)

State Agency of Medicines of the Republic of Latvia registers RIGVIR®

Oncolytic virotherapy with RIGVIR^® is reimbursable medication

State Agency of Medicines of the Republic of Latvia registers RIGVIR^®